ORAMED PHARMACEUTICALS INC.
Oramed Pharmaceuticals is a pharmaceutical company focused on researching and developing oral delivery of therapeutic proteins, including insulin. Its ORMD-0801 is an orally ingestible insulin capsule intended to deliver insulin through the gastrointestinal tract. Oramed also allocates capital to healthcare and life sciences investments and makes other investment and real estate transactions. Oramed earns money through investment-related arrangements, including royalties, revenue-sharing payments, interest on loans and fees for services. It also holds equity investments in other companies and participates in real estate investments. Following a transaction completed on March 25, 2026, Oramed transferred its Protein Oral Delivery technology platform and related assets to OraTech, a Lifeward subsidiary, while retaining responsibility for managing the clinical study of OraTech’s oral insulin product. Oramed is headquartered in New York, New York.
No SEC Form 4 filings for $ORMP in the last 30 days.
See all $ORMP insider activity →Oramed reported no revenue and a 62% decline in net income for 3Q 2026, with net income of $18.41M and EPS of $0.43. The decrease was due to Scilex revaluation losses and other factors, partially offset by Alpha Tau gains and a Scilex fee. Cash reserves were $28.9M, expected to last 12 months.
ORAMED PHARMACEUTICALS INC. (ORMP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 15, 2026, the Company held its 2026 Annual Meeting of Stockholders. The final voting results at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) are set forth below. Proposal No. 1 - Re-ele
NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ORMP (ORAMED PHARMACEUTICALS INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent ORMP coverage spans financial news, market movers and earnings.
Earnings miss with zero revenue likely triggers sell pressure.
Routine corporate governance outcomes with no immediate financial impact.
Improved earnings signal operational progress.
Routine 10b5-1 insider sale provides limited signal; it may slightly affect sentiment but is unlikely to change fundamentals.
Index inclusion and balance-sheet/portfolio updates can support liquidity and sentiment, but the letter is not a new financial print.
AlphAI scores every news story that mentions ORMP with an AI model for sentiment and relevance, and aggregates insider trades from ORAMED PHARMACEUTICALS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oramed reported no revenue and a 62% decline in net income for 3Q 2026, with net income of $18.41M and EPS of $0.43. The decrease was due to Scilex revaluation losses and other factors, partially offset by Alpha Tau gains and a Scilex fee. Cash reserves were $28.9M, expected to last 12 months.
ORAMED PHARMACEUTICALS INC. (ORMP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 15, 2026, the Company held its 2026 Annual Meeting of Stockholders. The final voting results at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) are set forth below. Proposal No. 1 - Re-ele
NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.
Hexter Joshua (COO & CBO) sold 137,000 shares of ORAMED PHARMACEUTICALS INC. (ORMP) at $4.46 ($0.61M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
Oramed Pharmaceuticals said in a shareholder letter it will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2026. The company reported its Alpha Tau (DRTS) position is up about $128 million to ~$167 million (incl. warrants), and that its Scilex (SCLX) $99.5 million loan has been substantially repaid, with ~$43 million expected by Oct. 2026. Oramed also cited total cash and assets of about $270 million as of March 31, 2026.
Oramed Pharmaceuticals (NASDAQ: ORMP) said it will be added to the Russell 2000 and Russell 3000 indexes after the 2026 semi-annual reconstitution, effective at the market open June 29, 2026. FTSE Russell’s preliminary additions were posted May 22, with final changes after June 26 close. Russell membership can also trigger inclusion in Russell 1000/2000 and style indexes, according to FTSE Russell.
Oramed Pharmaceuticals Inc.'s Chief Scientific Officer, Miriam Kidron, reported a tax-related disposition of 435,084 common shares to cover tax withholding obligations from vested Restricted Stock Units. The shares were valued at $3.31 each. Following this transaction, Kidron directly holds 1,133,138 shares of Oramed common stock.
Oramed Pharmaceuticals Inc. announced that Scilex Holding Company has completed the repurchase of all remaining warrants previously held by Oramed to purchase shares of Scilex common stock, totaling $28.5 million for 6,500,000 shares. This transaction involved two tranches, with Scilex paying $14 million on December 30 for 3,370,000 warrants and an earlier $13 million on September 30 for 3,130,000 warrants, plus $1.5 million in option fees. These repurchases were part of an option agreement disclosed in July and follows other strategic adjustments for Oramed, including the termination of a joint venture and plans to independently advance its oral insulin program.
Oramed Pharmaceuticals finalized a warrant repurchase with Scilex totaling $28.5 million on December 30, 2025. This involved Scilex repurchasing 3,370,000 shares for $14 million and an initial tranche of 3,130,000 shares for $13 million, with each tranche including a $750,000 option fee. The details of this transaction were filed with the SEC.
Oramed Pharmaceuticals Inc. (ORMP) announced that Leonard Sank, a long-serving director, will resign from its board effective January 1, 2026, after 18 years. The company stated this departure is not due to disagreements, indicating a smooth governance transition despite the loss of a long-tenured board member. TipRanks' AI Analyst, Spark, rates ORMP as Neutral, citing a strong balance sheet but weak operations and continued cash burn.
